Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046054 vs Docetaxel in Previously-Treated PD-L1 Positive NSCLC
NCT07144280Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of SGN-PDL1V in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Overall Survival at 5 years. Started Sep 2025; status: recruiting.
02
Drugs
SGN-PDL1V
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07144280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144280.